Cdc25A is involved in ciclopirox-induced inhibition of cancer cell proliferation

Tao Shen^{1,2}, Chaowei Shang^{1,2}, Hongyu Zhou¹, Yan Luo^{1,3}, Mansoureh Barzegar¹, Yoshinobu Odaka^{1,2}, Yang Wu^{1,3}, Shile Huang^{1,2,*}

Supplementary figures



Figure S1: CPX induces accumulation of MDA-MB-231 cells at G₁ phase of the cell cycle. MDA-MB-231 cells were exposed to CPX (0 and 5 μ M) for 24 h, followed by cell cycle analysis.



Figure S2: CPX downregulates the cellular protein level of Cdc25A in tumor cells in a concentration-dependent manner. HT29 and A549 cells were treated with CPX (0-20 μ M) for 24 h, followed by Western blotting with indicated antibodies.



Figure S3: CPX does not reduce Cdc25A mRNA level or protein synthesis significantly, but promotes Cdc25A protein degradation remarkably. (A) Rh30 cells were treated with CPX (0-20 μM) for 24 h. Total mRNA was extracted, followed by RT-PCR. β-actin was used as internal control. (B) Rh30 cells were treated with CPX at 0-20 μM for 30 h, and then pulsed with ³⁵S-Met/Cys for 6 h in the presence of CPX (0-20 μM). The proteins in the cell lysates were subjected to SDS-PAGE and transferred to a PVDF membrane, followed by autoradiography. GAPDH served as a control. (C) Rh30 cells were treated with 50 μg/ml cycloheximide (CHX), in the presence or absence of 10 μM CPX, for 0-24 h, followed by Western blotting with indicated antibodies. β-tubulin was used as a loading control. NIH Image J was used for semi-quantitative analysis of the intensities of the bands. Results are means ± SE and are pooled from three independent experiments. ^aP < 0.05, difference *versus* control group. ^bP < 0.05, difference *versus* CHX group.



Figure S4: Inhibition of proteasome with MG132 prevents CPX from reducing Cdc25A protein level. MDA-MB-231 cells were treated with or without CPX (10 μ M) for 24 h, in the presence or absence of MG132 (10 μ M), followed by Western blotting with indicated antibodies.



Figure S5: CPX-induced Cdc25A phosphorylation contributes to its degradation. (A) MDA-MB-231 cells were treated with CPX (5 μ M) for 0-24 h, followed by Western blotting with indicated antibodies. (B) MDA-MB-231 cells, infected with indicated recombinant adenoviruses, were treated with or without CPX (5 μ M) for 24 h, followed by Western blotting with indicated antibodies. β -tubulin was used as a loading control.



Figure S6: Ectopic expression of Cdc25A mutant (S82A) renders resistance to CPX inhibition of cell proliferation. (A, B) MDA-MB-231 cells, infected with indicated recombinant adenoviruses, were treated with 5 μ M of CPX for 24 h, followed by Western blotting with indicated antibodies (A), and MTS assay (B). All data represent the means \pm SE (n=3). **P*< 0.05.